Organogenesis Holdings Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ORGO | LFCR | ARX.AX | ELUT | MDXG | BSEM | |
|---|---|---|---|---|---|---|
| Market cap | 111.95M | 244.11M | 171.82M | 33.64M | 466.96M | 21.47M |
| P/E (TTM) | — | — | 49.0 | — | — | 1.3 |
| Forward P/E | -2.8 | -8.3 | 16.8 | -0.7 | 30.0 | 4.0 |
| Price/book | 0.8 | -3.3 | 2.1 | 2.1 | 2.2 | 0.7 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −78.97% | −5.17% | −38.22% | −19.32% | −59.17% | −71.95% |
| Today | +4.19% | +0.31% | +1.03% | −6.59% | −1.54% | 0.00% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 20 min.
Latest news
All ORGO news ›Spatial mapping reveals how human urogenital organs codevelop during organogenesis
A new study has mapped human urogenital development in its native spatial context, revealing how neighboring organs coordinate their development through cellular communication and molecular signaling during embryogenesis. The study,…
Organogenesis Announces Publication of Peer-Reviewed PREPARE Trial Results Demonstrating Clinical Benefit of PuraPly®AM for Hard-to-Heal Diabetic Foot Ulcers
Organogenesis Announces Publication of Peer-Reviewed PREPARE Trial Results Demonstrating Clinical Benefit of PuraPly®AM for Hard-to-Heal Diabe
Organogenesis Announces Publication of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit of Affinity™ in the Most Challenging and Complex Venous Leg Ulcers
Organogenesis Announces Publication of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit of Affinity⢠in the Most Challenging and Complex Venous Leg Ulcers Organogenesis Announces Publication of Peer-Reviewed Clinical…
Truist Financial Keeps Their Hold Rating on Organogenesis Holdings (ORGO)
Truist Financial analyst Ravi Misra reiterated a Hold rating on Organogenesis Holdings today and set a price target of $2.00. According to TipRanks, Misra is an analyst with an average return of -10.7% and a 35.00% success rate. Misra…
Diabetic Foot Ulcers Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight by DelveInsight | Medline, B. Braun, Organogenesis, 3M, Smith & Nephew, Molnlycke Health
Albany New York October 19 2026 As per DelveInsight s assessment globally Diabetic Foot Ulcers pipeline constitutes 20 key companies continuously working towards developing 25 Diabetic Foot Ulcers treatment therapies analysis of Clinical…
Organogenesis Holdings (ORGO) Battles Headwinds: Can This Regenerative Medicine Innovator Stage a Comeback?
Canton, MA – Organogenesis Holdings Inc. (NASDAQ: ORGO), a prominent player in the regenerative medicine sector, has recently endured a period of significant stock weakness, leaving investors ...
Organogenesis Announces Publication Of Peer-Reviewed Prepare Trial Results
TradingView Organogenesis Announces Publication Of Peer-Reviewed Prepare Trial Results
Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2026 Financial Results on November 5, 2026
Results are scheduled after market close Nov. 5, followed by a 5 p.m. ET call and corporate update; the webcast will be archived for about a year. - Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2026 Financial Results…
DNA Typewriter, PEtracer Map Mouse Development Through Organogenesis
DNA Typewriter and PEtracer reconstruct mouse cell lineages at high resolution, revealing when cell fates diverge during embryonic development. Researchers have used two DNA-recording systems to reconstruct cellular family trees across…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- markets.businessinsider.com5
- bostonglobe.com1
- investors.organogenesis.com1
- markets.financialcontent.com1
- openpr.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 12 articles, not a forecast.